Health Utilities and Costs for Multiple Sclerosis

A survey of 5,913 MS patients revealed a mean utility score of 0.576. The highest scores were for relapsing-remitting MS at 0.667, while secondary progressive MS had the lowest at 0.385. Total MS-related costs over three months averaged £2807, with costs ranging widely based on disability status (EDSS).

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42843719)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

These findings help quantify health-related quality of life and economic burden in MS patients, with significant differences across MS types. This data can inform healthcare decision-making and resource allocation.

What this does not prove

The study does not establish causal relationships and does not fully explore variability related to age, sex, MS types, and EDSS scores beyond reported data.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Observational
Participants / samples: 5913 · patients who returned survey questionnaires
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: RRMS, SPMS, PPMS
Publication date: 2026-10-07
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Primary evidenceHealth Utilities and Costs for Multiple Sclerosis. ↗DOI: 10.1016/j.jval.2026.08.015

Supporting passages (9)

study designData were analysed descriptively and using regression models.

subjectsMETHODS: Patients with MS recruited to the Trajectories of Outcomes in Neurological Conditions (TONiC-MS) study completed a survey that included the EuroQoL EQ-5D-5L, EQ VAS, and a resource use questionnaire for recording their use of MS-related primary, secondary and community care services, diagnostic tests and medicines in the previous 3 months.

sample size5,913 (58.9%) returned their survey questionnaires.

sample size basisOf 10,031 patients invited to participate, 5,913 (58.9%) returned their survey questionnaires.

peer reviewedJournal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

relevant ms typesThese were highest for those with relapsing remitting MS 0.667 (0.659, 0.675) and lowest in secondary progressive MS 0.385 (0.368, 0.402).

publication date2026-10-07

findingsOverall, participants' mean (95% CI) utilities scores were 0.576 (0.568, 0.583).

limitationsTitle: Health Utilities and Costs for Multiple Sclerosis.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.